Fabio
91 lines
5.2 KiB
Markdown
91 lines
5.2 KiB
Markdown
---
|
||
type: "Bill"
|
||
title: "Active Pharmaceutical Ingredient Manufacturing Grant Fund; established."
|
||
description: "Active Pharmaceutical Ingredient Manufacturing Grant Fund. Establishes the Active Pharmaceutical Ingredient Manufacturing Grant Fund to provide grant installment awards between July 1, 2026, and July 1, 2045, in an amount not to exceed $15 million per fiscal year and in an aggregate amount not to exceed $130 million, to a qualified company that (i) engages in the manufacture of pharmaceutical substances, (ii) executes a memorandum of understanding with the Commonwealth, and (iii) is expected to make a capital investment of at least $2,148,793,019 and create and maintain at least 468 new full-time jobs. This bill is identical to SB 404."
|
||
jurisdiction: "us/states/va"
|
||
legislature: "Virginia General Assembly"
|
||
session: "2026"
|
||
identifier: "HB 800"
|
||
citation: "Virginia HB 800 (2026)"
|
||
classification: ["bill"]
|
||
subjects: []
|
||
status: "enacted"
|
||
primary_sponsors: ["Luke E. Torian"]
|
||
version_count: 2
|
||
action_count: 27
|
||
vote_count: 6
|
||
first_action: "2026-01-13"
|
||
last_action: "2026-04-13"
|
||
source: "openstates"
|
||
source_identifier: "ocd-bill/660a7b4a-cc6d-4faf-a2d5-6046ccc3d1e2"
|
||
source_url: "https://lis.virginia.gov/bill-details/20261/HB800"
|
||
source_hash: "97bfc70ae54f60ca93dbced422ee1647e083de1d6a0a1a42d5fb0ee2d8fd7add"
|
||
vintage: "2026-07-01"
|
||
source_snapshot: "https://data.openstates.org/daily/2026-07-01/public.pgdump"
|
||
retrieved_at: "2026-07-06"
|
||
confidence: "reported"
|
||
tags: ["legislation", "bill", "us-va"]
|
||
---
|
||
|
||
# Virginia HB 800 (2026) — Active Pharmaceutical Ingredient Manufacturing Grant Fund; established.
|
||
|
||
Active Pharmaceutical Ingredient Manufacturing Grant Fund. Establishes the Active Pharmaceutical Ingredient Manufacturing Grant Fund to provide grant installment awards between July 1, 2026, and July 1, 2045, in an amount not to exceed $15 million per fiscal year and in an aggregate amount not to exceed $130 million, to a qualified company that (i) engages in the manufacture of pharmaceutical substances, (ii) executes a memorandum of understanding with the Commonwealth, and (iii) is expected to make a capital investment of at least $2,148,793,019 and create and maintain at least 468 new full-time jobs. This bill is identical to SB 404.
|
||
|
||
## Version chain
|
||
|
||
The bill's text revisions, in order — the diff chain from filing to enrollment.
|
||
|
||
1. **Introduced** (filed) — [source](https://lis.blob.core.windows.net/files/1085951.PDF)
|
||
2. **Enrolled** (enrolled) — [source](https://lis.blob.core.windows.net/files/1171569.PDF)
|
||
|
||
## Votes
|
||
|
||
- Constitutional reading dispensed (on 2nd reading) — **38–0** (pass) · upper
|
||
- H VOTE: — **94–3** (pass) · lower
|
||
- Reported from Appropriations — **20–0** (pass) · lower
|
||
- Subcommittee recommends reporting — **5–0** (pass) · lower
|
||
- Reported from Finance and Appropriations — **13–0** (pass) · upper
|
||
- Passage R — **39–0** (pass) · upper
|
||
|
||
## Sponsors
|
||
|
||
- Luke E. Torian — primary (person)
|
||
- Virgil Thornton — cosponsor (person)
|
||
|
||
## Timeline
|
||
|
||
The legislative action history — every referral, reading, and vote.
|
||
|
||
- **2026-01-13** Prefiled and ordered printed; Offered 01-14-2026 26102907D `filing, introduction`
|
||
- **2026-01-13** Referred to Committee on Appropriations `referral-committee`
|
||
- **2026-01-20** Assigned HAPP sub: Commerce Agriculture & Natural Resources `referral-committee`
|
||
- **2026-01-23** Fiscal Impact Statement from Department of Planning and Budget (HB800)
|
||
- **2026-01-28** Subcommittee recommends reporting (5-Y 0-N)
|
||
- **2026-01-30** Reported from Appropriations (20-Y 0-N) `committee-passage`
|
||
- **2026-02-03** Read first time `reading-1`
|
||
- **2026-02-04** Moved from Uncontested Calendar to Regular Calendar
|
||
- **2026-02-04** Read second time and engrossed `reading-2`
|
||
- **2026-02-05** Read third time and passed House (94-Y 3-N 0-A) `passage, reading-3`
|
||
- **2026-02-06** Constitutional reading dispensed (on 1st reading)
|
||
- **2026-02-06** Referred to Committee on Finance and Appropriations `referral-committee`
|
||
- **2026-02-17** Reported from Finance and Appropriations (13-Y 0-N) `committee-passage`
|
||
- **2026-02-18** Read second time `reading-2`
|
||
- **2026-02-18** Rules suspended
|
||
- **2026-02-18** Constitutional reading dispensed Block Vote (on 2nd reading) (38-Y 0-N 0-A)
|
||
- **2026-02-18** Passed by for the day
|
||
- **2026-02-19** Read third time `reading-3`
|
||
- **2026-02-19** Passed Senate Block Vote (39-Y 0-N 0-A) `passage`
|
||
- **2026-02-23** Enrolled `enrolled`
|
||
- **2026-02-23** Bill text as passed House and Senate (HB800ER) `passage`
|
||
- **2026-02-23** Fiscal Impact Statement from Department of Planning and Budget (HB800)
|
||
- **2026-02-23** Signed by Speaker `passage`
|
||
- **2026-02-23** Signed by President `passage`
|
||
- **2026-03-10** Enrolled Bill communicated to Governor on March 10, 2026 `enrolled, executive-receipt`
|
||
- **2026-03-10** Governor's Action Deadline 11:59 p.m., April 13, 2026 `executive-receipt`
|
||
- **2026-04-13** Approved by Governor-Chapter 804 (effective 7/1/2026) `executive-signature`
|
||
|
||
## Source
|
||
|
||
OpenStates / OpenCivicData bulk snapshot [2026-07-01](https://data.openstates.org/daily/2026-07-01/public.pgdump); origin `ocd-bill/660a7b4a-cc6d-4faf-a2d5-6046ccc3d1e2`. Confidence: reported (aggregated from official Virginia legislature records).
|
||
|